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Abstract
Background Antiprothrombin antibodies detection comprises two different ELISAs: prothrombin coated on irradiated plates (aPT) or phosphatidylserine/prothrombin (aPS/PT) as the antigen. While several commercial kits are available for the detection of aPT, aPS/PT are usually detected by in-house assays. Recently, a new commercially available kit was launched and, therefore, we decided to test its efficiency by comparing it to our in-house assay.
Methods aPS/PT were tested by our in-house assay (aPS/PT ih ) in 75 SLE patients, using Immulon 1 plates coated with phosphatidylserine, purified human prothrombin and 1%BSA-TBS-CaCl as blocking and diluents. Data from this assay were compared to those obtained by the QUANTA Lite™ aPS/PT screen, IgG and IgM Elisa (INOVA Diagnostics, Inc, San Diego, USA) commercial kits (aPS/PT c ). 
Results

aPS
Introduction
In clinical practice, anticardiolipin antibody (aCL), antiβ2glycoprotein I (aβ2GPI), detected by enzyme-linked immunosorbent assay (ELISA) and the lupus anticoagulant (LA) detected by clotting assays have been the tests of choice for the diagnosis of the antiphospholipid syndrome (APS). However, antiphospholipid antibodies (aPL) are a heterogeneous family of immunoglobulins that do not bind to phospholipids but to plasma proteins with affinity for anionic surfaces (i.e. phospholipids). Evidence gathered through years of work suggests that aPL are directed against specific phospholipid binding plasma proteins such as β2 glycoprotein I and prothrombin, among others [1] and [2] . Antibodies to prothrombin are frequently found in patients with systemic lupus erythematosus (SLE) and have been associated with thrombosis and recurrent pregnancy loss [3] and [4] . Antiprothrombin antibodies are commonly detected by ELISA, using irradiated plates (aPT) [3] and [5] or in complex with phosphatidylserine (aPS/PT) [3] , [6] and [7] . The mode of presentation of prothrombin in solid phase seems to influence its recognition by antiprothrombin antibodies. In fact, antiprothrombin antibodies cannot bind when prothrombin is immobilised onto non-irradiated plates [5] and [6] , but do so if prothrombin is immobilised on a suitable anionic surface, adsorbed on gamma irradiated plates or exposed to immobilised anionic phospholipids. While several commercial kits are available for the detection of aPT, aPS/PT are usually detected by in-house assays. Recently, a new aPS/PT commercially available kit was launched and, therefore, we decided to test its efficiency and analyse its clinical performance by comparing the results to our in-house assay in a cohort of patients with SLE.
Patients and Methods
This study included 75 consecutive patients, all fulfilling the 1982 criteria for SLE [8] . Of these, 37 patients fulfilled criteria for definite APS [9] and [10] . Patients group comprised 70 female and 5 male with a mean age of 43.7 ± 11.9 years and mean disease duration of 13.1 ± 9.1 years. Overall, 46 patients had a history of thrombosis, including 18 arterial, 15 venous and 13 both arterial and venous thrombosis. Out of 49 women who had ever been pregnant, 16 had a history of miscarriages and 20 a history of fetal death. Demographics are summarised in Table 1 . Ethical approval was obtained from the Guy's and St Thomas' Ethics committee and all patients involved in this study gave their written consent.
Blood Collection
Blood was collected by venopuncture from the antecubital vein into pre-cooled tubes containing 0.105 M sodium citrate and in non-anticoagulated tubes (Hemogard® 9NC and Hemogard® Z, respectively, Becton Dickinson, Rutherford, USA). Platelet free plasma was obtained by centrifugation at 2500 g for 20 minutes and filtration using a 0.2 μm surfactant free cellulose acetate membrane (Nalgene, Rochester, NY, USA). Plasma was stored at − 80 °C until used. For sera preparation, blood was allowed to clot at room temperature and then centrifuged at 2000 g for 20 minutes. Sera were subsequently aliquoted and stored frozen at − 80 °C until use.
Antibodies to Phosphatidylserine-Prothrombin
Antibodies were tested by an in-house assay (aPS/PT ih ) and by a commercially available kit (aPS/PT c ).
aPS/PT ih were tested as previously reported [3] . Briefly, Microtitre ELISA plates (Immulon 1, Dynatech, Virginia, USA) were coated with 30 μl of 50 μg/ml phosphatidylserine (Sigma) in methanol/chloroform (4:1) overnight at 4 °C. After blocking with 1% bovine serum albumine in Tris buffer saline and 5 mM CaCl2 (1%BSA-TBS-CaCl2), plates were washed twice with TBS-5 mM CaCl2-0.005% Tween and 10 μg/ml purified human prothrombin (Enzyme Research Laboratories Inc, Swansea, UK) were added and incubated at 37 °C. After one hour, serum samples diluted 1:100 in 1%BSA-TBS-CaCl2 were added in duplicate. Plates were incubated for one hour, followed by alkaline phosphatase-conjugated goat anti-human IgG or IgM (Sigma) and substrate. 
Other aPL
The aCL and anti-β2GPI ELISAs were performed according to the current recommendations [2] and [11] . Anti-β2GPI were detected by ELISA as described previously [12] , using irradiated microtitre plates (Nunc Maxisorp, Denmark). Plasma samples were tested for the presence of LA according to the recommended criteria from the ISTH Subcommittee on Lupus Anticoagulant-Phospholipid-dependent antibodies [13] and [14] . Fig. 1 . There was a positive correlation between IgG aPS/PTih and aPS/PTc by Spearman test (R2 = 0.861, p = 0.0027) ( Fig. 2A) . Although less strong than that found for the IgG isotype, a positive correlation was also seen between IgM aPS/PTih and aPS/PTc (R2 = 0.54, p = 0.003) (Fig. 2.B) . Sensitivity and specificity for APS were 62.2% and 97.4% (AUC 0.780) for the aPS/PTih and 70.3% and 84.2% (AUC 0.858) for the aPS/PTc, respectively. The presence of aPS/PT by both, aPS/PTih and aPS/PTc was associated with thrombosis. All data are summarised in Table 4 .
Discussion
In this study we aimed to test the efficiency and analyse the clinical performance of a new commercially available kit for aPS/PT testing by comparing the results to our in-house assay. aPS/PT have been previously reported to be associated with thrombosis and recurrent pregnancy loss [3] , [6] and [7] . Recent data from our group [15] confirms that their inclusion in the panel of antibodies tested for APS can result in a higher diagnostic power and in helping to stratify the thrombotic risk in patients with SLE. To the best our knowledge, no commercial ELISA test has been previously evaluated and this is the first study testing the clinical accuracy of a commercial kit for aPS/PT. As these antibodies are not part of the routinely tested panel of aPL and no consensual standardized method exists for their detection, the validation of an available commercial kit is largely desirable. In this study, the comparison of the overall diagnostic performance by AUCs, a conventional method [16] , confirmed that both the assays, aPS/PTih and aPS/PTc, reached a good level of accuracy (AUC 0.780 and 0.858, respectively), and were able to identify patients with APS, both in terms of thrombosis and/or pregnancy loss. Although sensitivity and specificity were similar between the two assays, the aPS/PTcassays showed a slightly higher number of positive results, with the consequential higher sensitivity to the expense of the specificity. We report that the aPS/PTc ELISA test is also a rapid and simple method. The mean-time of the analysis is reduced with the commercial method which includes fewer time-consuming procedures (data not shown). This results in the reduction of potential analytical variables thanks to a simpler protocol and a shorter testing time. In addition, it offers a valid diagnostic tool for APS diagnosis mainly for those centres where in-house assays are not available or affordable. In addition to these technical advantages, adopting a commercial kit may help in guaranteeing the comparability of results between laboratories, although a closer collaboration with kit companies is necessary for the success of this sort of initiative. While the need for routine testing for aPS/PT is still under debate, there is overwhelming clinical evidence that these antibodies are associated with thrombosis and pregnancy loss in patients with APS and that their presence increases the risk of developing such an event [17] , [18] and [19] . Therefore, the technical assessment of available methods for the detection is timely.
In conclusion, the results of this study demonstrated that the analysed commercially available ELISA kit is a satisfactory and time-effective method for the testing of aPS/PT, at least when compared to our in-house assay. SLE: systemic lupus erythematosus, APS: antiphospholipid syndrome, *some patients fulfil criteria for both SLE and APS, † 13 patients from each group have both arterial and venous thrombosis, ‡ pregnancy loss defined by criteria [9] and [10] . All pregnancy data percentages calculated over the total number of female who had ever been pregnant (n = 49). IgG/IgM = IgG and/or IgM for both aCL and anti-β2GPI. 
+ -5 (6.6) aPS/PTih: in house assay; aPS/PTc: QUANTA Lite™ aPS/PT kit; + = positive; -= negative. *and/or = any isotype. Table 4 . aPS/PT in thrombosis and pregnancy loss (PL).
*PL: pregnancy loss. All pregnancy data are calculated over the total number of female who had ever been pregnant (n = 49).
